Dear Jeppe,

thanks for sending the quote request. Please note the limit option can be offered in both cases, non-compulsory or obligatory insurance AMG. We’ll attach both General Terms & Conditions (AVB) to our offer. But latest with the binder we need to know if insurance coverage is legally required by AMG/MPG or not, because of the different AVB.

We herewith offer a clinical trials insurance for the following trial:

**Study Title: Agents Intervening against Delirium in the Intensive Care Unit, randomized, stratified,parallel-grouped, blinded, placebo-controlled trial**

**Protocol No.: AID-ICU**

**Start Date: xx.xx.2018**

**End Date:   xx.xx.xxxx max. 3 years**

**This Quotation is based on the number of Patients: 200**

**Policyholder:**

**Center for Research in Intensive Care**

**Limit and Premium:**

1. Limit: Max. 5.000.000 EUR for the clinical trial if up to 1.000 test persons participate ; **500.000 EUR per proband**Limit: Max. 10.000.000 EUR for the clinical trial if between 1.000 and 3.000 test persons participate.
Limit: Max. 15.000.000 EUR for the clinical trial if more than 3.000 test persons participate.

Premium: **Minimum premium**: **5.000,00 EUR**. Premium for each proband: **55,00 EUR** per proband

**For the insurance following conditions apply:**

The premium is subject to premium adjustment after the end of the study based on the final number of patients.

All premiums are net of taxes and**without broker commission.**

**Condition: The study has not started yet** **.**

The wording is the German standardized proband wording which is used on the German market.

* German law is applicable.
* Punitive damages and compensation for pain and suffering are excluded.
* Court of jurisdiction is Munich, Germany.
* Coverage is subject to the version of the protocoll dated 01.12.2017.
* Changes in the content or duration of the clinical trial have to be notified to and approved by the insurer.
* A positive vote of the ethics commission and approval of the higher federal authority for conducting this clinical trial are prerequisite for the coverage. The coverage ends by the time the higher federal authority withdraws, cancels or puts the approval to rest.
* Binding period is 21 days from 20.04.2018.
* Beginning of the study is not later than 12 months after the acceptance of the offer.
* Notification of the final patient number to the insurer.
* A cancellation of the policy will result in a handling fee in the amount of 1.000 EUR.

Please also let us know if the client does not accept the offer.

We look forward to hearing from you.

Best regards

Markus
\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_



 **Markus Friedmann**

Allianz Global Corporate & Specialty SE

Account Technician Liability
Global Clients Unit Germany

Besucher / Visitors: Cäcilienkloster 8, 50676 Köln

Tel +49.89.20305.3112 | Fax +49.89.20305.03112

Post: Postfach 10 01 61, 50441 Köln
markus.friedmann@allianz.com

[www.agcs.allianz.com](http://www.agcs.allianz.com/)  |  Abonnieren Sie unseren Newsletter: [agcs.momentum](http://www.agcs.allianz.com/momentum)

Folgen Sie AGCS auf:

    

Allianz Global Corporate & Specialty SE | Registered office/Sitz: Koeniginstrasse 28, 80802 Munich, Germany | Commercial Register/Handelsregister: Munich HRB 208312.
For VAT purposes /für Umsatzsteuerzwecke: VAT ID number/USt-ID-Nr.: DE 811 150 901. Financial and insurance services are tax exempt under the UstG/EU VAT Directive/Finanz- und Versicherungsleistungen i.S.d. UStG/MwStSystRL sind steuerbefreit.
Chairman of the Supervisory Board/Vorsitzender des Aufsichtsrats: Niran Peiris | Board of Management/Vorstand: Chris Fischer Hirs (Chairman/Vorsitzender), Andreas Berger, Sinéad Browne, Nina Klingspor, Alexander Mack, Hartmut Mai, Paul O’Neill, William Scaldaferri, Carsten Scheffel.